Cognitive Effects of Atomoxetine in Humans: Genetic Moderators

This will be a double-blind, placebo-controlled, crossover study, with cocaine use (cocaine
users vs. healthy controls) and NET AAGG4 status (L4/ L4 vs. L4/S4 or S4/ S4 genotype) as
the between-subject factors. Similar to previous studies, we propose to compare individuals
with two copies of the L4 allele to participants with at least one S4 allele because only
less than two percent of the general population is homozygous for the S4 allele. Forty
cocaine users and 40 healthy controls will participate in 3 test sessions, where they will
be assigned to 40 mg atomoxetine, 80 mg atomoxetine, or placebo. Outcome measures will
include physiological, subjective, and cognitive performance measures.

Currently recruiting with 24completers and two active. (February 2013)

Inclusion Criteria:

- Male and females, between the ages of 21 and 50;

- No current dependence or abuse of drugs of abuse or alcohol (except and tobacco);

- No current medical problems and normal ECG;

- For women, not pregnant as determined by pregnancy screening nor breast feeding, and
using acceptable birth control methods.

Exclusion Criteria:

- Current major psychiatric illnesses including mood, psychotic, or anxiety disorders;

- History of major medical illnesses; including liver diseases, heart disease, or other
medical conditions that the physician investigator deems contraindicated for the
subject to be in the study;

- Known allergy to Atomoxetine;

- Use of Monoamine Oxidase inhibitor within the last month (clinically Atomoxetine
administration is contraindicated with or within 2 weeks of discontinuation of
Monoamine oxidase inhibitor therapy).